Opus Genetics, Inc.
NASDAQ:IRDBiotechnology
-$0.01 today
- Market cap
- $326.13M
- Beta
- 0.55
- P/E (TTM)
- -33.0
- EPS (TTM)
- -$0.12
Volume 0.75M
Average 0.81M
IRD Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
Opus Genetics, Inc.NASDAQ: IRD
Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026
Accumulated OCI remains negative
Q1 FY2026 Accumulated OCI was $0, compared with $0 a year earlier.
Context
- Accumulated OCI amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Accumulated OCI increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Accumulated OCI vs competitors
How IRD compares with its peers on the latest reported figures
- IRD's Mar 2026 Accumulated OCI of $0 is the 2nd highest of the 10 companies compared; the peer median is -$64K.
- Accumulated OCI amounts to 0.0% of total assets for IRD, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $21K | +40.0% | — | 0.0% | |
IRDOpus Genetics, Inc. | Mar 2026 | $0 | — | — | 0.0% |
| Mar 2026 | $0 | +100.0% | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | -$64K | -121.0% | — | 0.0% | |
| Mar 2026 | -$104K | -154.5% | — | 0.0% | |
| Mar 2026 | -$437K | +70.2% | — | 0.2% | |
| Mar 2026 | -$532K | -18.0% | — | 0.3% | |
| Mar 2026 | -$636.09K | +3.8% | — | 1.3% | |
| Peer median (excluding IRD) | -$64K | +3.8% | — | 0.0% | |
Competitors are the stored peer set for IRD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Opus Genetics, Inc.
NASDAQ:IRD
Intrinsic Alpha fair value
Locked
Current Price
$3.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.